Glycosylated copper(ii) ionophores as prodrugs for β-glucosidase activation in targeted cancer therapy

Valentina Oliveri, Maurizio Viale, Giulia Caron, Cinzia Aiello, Rosaria Gangemi, Graziella Vecchio

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

8-Hydroxyquinoline derivatives are metal-binding compounds that have recently attracted interest as therapeutic agents for cancer therapy. In this scenario, we designed and synthesized three new glucoconjugates, 5,7-dichloro-8-quinolinyl-β-d-glucopyranoside, 5-chloro-8-quinolinyl- β-d-glucopyranoside and 2-methyl-8-quinolinyl-β-d-glucopyranoside and investigated their biological properties in comparison to the parent 8-hydroxyquinoline derivatives in the presence of Cu2+. In vitro data show that 2 out of 3 glycosylated compounds possess a pharmacologically- relevant antiproliferative activity against tumor cells, similar to that of their parent compounds; this activity is associated with a relevant triggering of apoptosis. The pharmacological profile of the glucoconjugates depends on the cellular enzymatic β-glucosidase activity, as demonstrated by the inhibition of antiproliferative activity in the presence of the 2,5-dideoxy-2,5-imino-d-mannitol.

Original languageEnglish
Pages (from-to)2023-2034
Number of pages12
JournalDalton Transactions
Volume42
Issue number6
DOIs
Publication statusPublished - Feb 14 2013

Fingerprint

Glucosidases
Oxyquinoline
Ionophores
Prodrugs
Copper
Chemical activation
Derivatives
Mannitol
Tumors
Metals
Cells
Apoptosis

ASJC Scopus subject areas

  • Inorganic Chemistry

Cite this

Glycosylated copper(ii) ionophores as prodrugs for β-glucosidase activation in targeted cancer therapy. / Oliveri, Valentina; Viale, Maurizio; Caron, Giulia; Aiello, Cinzia; Gangemi, Rosaria; Vecchio, Graziella.

In: Dalton Transactions, Vol. 42, No. 6, 14.02.2013, p. 2023-2034.

Research output: Contribution to journalArticle

Oliveri, Valentina ; Viale, Maurizio ; Caron, Giulia ; Aiello, Cinzia ; Gangemi, Rosaria ; Vecchio, Graziella. / Glycosylated copper(ii) ionophores as prodrugs for β-glucosidase activation in targeted cancer therapy. In: Dalton Transactions. 2013 ; Vol. 42, No. 6. pp. 2023-2034.
@article{35a5e228f7394b1a9a84333c4e3df948,
title = "Glycosylated copper(ii) ionophores as prodrugs for β-glucosidase activation in targeted cancer therapy",
abstract = "8-Hydroxyquinoline derivatives are metal-binding compounds that have recently attracted interest as therapeutic agents for cancer therapy. In this scenario, we designed and synthesized three new glucoconjugates, 5,7-dichloro-8-quinolinyl-β-d-glucopyranoside, 5-chloro-8-quinolinyl- β-d-glucopyranoside and 2-methyl-8-quinolinyl-β-d-glucopyranoside and investigated their biological properties in comparison to the parent 8-hydroxyquinoline derivatives in the presence of Cu2+. In vitro data show that 2 out of 3 glycosylated compounds possess a pharmacologically- relevant antiproliferative activity against tumor cells, similar to that of their parent compounds; this activity is associated with a relevant triggering of apoptosis. The pharmacological profile of the glucoconjugates depends on the cellular enzymatic β-glucosidase activity, as demonstrated by the inhibition of antiproliferative activity in the presence of the 2,5-dideoxy-2,5-imino-d-mannitol.",
author = "Valentina Oliveri and Maurizio Viale and Giulia Caron and Cinzia Aiello and Rosaria Gangemi and Graziella Vecchio",
year = "2013",
month = "2",
day = "14",
doi = "10.1039/c2dt32429f",
language = "English",
volume = "42",
pages = "2023--2034",
journal = "Dalton Transactions",
issn = "1477-9226",
publisher = "Royal Society of Chemistry",
number = "6",

}

TY - JOUR

T1 - Glycosylated copper(ii) ionophores as prodrugs for β-glucosidase activation in targeted cancer therapy

AU - Oliveri, Valentina

AU - Viale, Maurizio

AU - Caron, Giulia

AU - Aiello, Cinzia

AU - Gangemi, Rosaria

AU - Vecchio, Graziella

PY - 2013/2/14

Y1 - 2013/2/14

N2 - 8-Hydroxyquinoline derivatives are metal-binding compounds that have recently attracted interest as therapeutic agents for cancer therapy. In this scenario, we designed and synthesized three new glucoconjugates, 5,7-dichloro-8-quinolinyl-β-d-glucopyranoside, 5-chloro-8-quinolinyl- β-d-glucopyranoside and 2-methyl-8-quinolinyl-β-d-glucopyranoside and investigated their biological properties in comparison to the parent 8-hydroxyquinoline derivatives in the presence of Cu2+. In vitro data show that 2 out of 3 glycosylated compounds possess a pharmacologically- relevant antiproliferative activity against tumor cells, similar to that of their parent compounds; this activity is associated with a relevant triggering of apoptosis. The pharmacological profile of the glucoconjugates depends on the cellular enzymatic β-glucosidase activity, as demonstrated by the inhibition of antiproliferative activity in the presence of the 2,5-dideoxy-2,5-imino-d-mannitol.

AB - 8-Hydroxyquinoline derivatives are metal-binding compounds that have recently attracted interest as therapeutic agents for cancer therapy. In this scenario, we designed and synthesized three new glucoconjugates, 5,7-dichloro-8-quinolinyl-β-d-glucopyranoside, 5-chloro-8-quinolinyl- β-d-glucopyranoside and 2-methyl-8-quinolinyl-β-d-glucopyranoside and investigated their biological properties in comparison to the parent 8-hydroxyquinoline derivatives in the presence of Cu2+. In vitro data show that 2 out of 3 glycosylated compounds possess a pharmacologically- relevant antiproliferative activity against tumor cells, similar to that of their parent compounds; this activity is associated with a relevant triggering of apoptosis. The pharmacological profile of the glucoconjugates depends on the cellular enzymatic β-glucosidase activity, as demonstrated by the inhibition of antiproliferative activity in the presence of the 2,5-dideoxy-2,5-imino-d-mannitol.

UR - http://www.scopus.com/inward/record.url?scp=84872550607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872550607&partnerID=8YFLogxK

U2 - 10.1039/c2dt32429f

DO - 10.1039/c2dt32429f

M3 - Article

C2 - 23174818

AN - SCOPUS:84872550607

VL - 42

SP - 2023

EP - 2034

JO - Dalton Transactions

JF - Dalton Transactions

SN - 1477-9226

IS - 6

ER -